Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07363811Recruiting
Nivolumab and immune cells in advanced lung cancer
This trial looks at the level of a specific type of immune cell (large granular lymphocytes) in people with advanced non-small cell lung cancer that has spread. It aims to see if these cells affect how well the drug nivolumab works. This could help doctors understand which patients benefit most from treatment.
Konya, MeramAges 18–90 - NCT07413757Recruiting
Study on factors in choosing lung cancer treatment
This study looks at what doctors and patients consider when deciding on a first-line treatment for advanced lung cancer. It aims to understand how choices are made for people taking a type of targeted therapy.
ChengduAges 18 years+ - NCT07452003Recruiting
Immunotherapy plus chemo before and after lung cancer surgery
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT06418412Recruiting
Pan-Asian study for EGFR exon 20 insertion lung cancer
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
SingaporeAges 21–99 - NCT01803542RecruitingPhase 2
Stereotactic radiation for lung metastases or early lung tumors
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
Toronto, OntarioAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT06008730RecruitingPhase 2
Proton beam radiation after lung cancer surgery
This trial tests if proton beam radiation therapy is safe and effective after surgery for non-small cell lung cancer that has spread to lymph nodes in the chest. It is for people who have already had chemotherapy before their surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT06923618Recruiting
Lung Cancer and Aging in Older Adults
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Créteil, Île-de-France RegionAges 70 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT07140315RecruitingPhase 1
DK222 study for lung and bladder cancer
This trial tests a new imaging drug, DK222, to see how well it works in people with non-small cell lung cancer or bladder cancer who are about to start immunotherapy. It may help doctors see if the treatment is reaching the right targets.
Baltimore, MarylandAges 18 years+ - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,103 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.